Minervax ApS

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

1 Completed trials

3 Countries active

2 Unique IMPs

100% Results reported

Phase II/III

Phase II/III: 2

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Group B streptococcus neonatal sepsis 2

Top IMPs

GBS-NN, GBS-NN2 2 DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE 1

All trials

2 total

GBS-NN/NN2 (50 μg of each fusion protein [GBS-NN and GBS-NN2] in combination with 500 μg Aluminum as Alhydrogel®) given with and without the… Pending

2023-508563-73-00 Phase II/III 2 countries DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPH…
A follow-up trial of GBS NN/NN2 vaccine in healthy pregnant women Ended

2024-516364-28-00 Phase II/III 1 country GBS-NN, GBS-NN2

Showing 1–2 of 2 trials

← All sponsors A–Z